Maurits Janssen

Maurits Janssen, Ph.D.

Vice President, Head of Commercial Development, API Development & Manufacturing
Lonza AG
Basel, Switzerland

Maurits Janssen is currently Vice President, Head of Commercial Development for the Active Pharmaceutical Ingredient (API) Business Unit at Lonza.

Mr. Janssen earned his Ph.D. in organic chemistry from Utrecht University in The Netherlands (1996) and subsequently fulfilled several functions with increasing responsibility in consulting, marketing & sales and research & development.

Mr. Janssen has over 20 year experience in chemical and pharmaceutical industry and over 15 years in the custom manufacturing of active pharmaceutical ingredients.

Throughout his career, Mr. Janssen worked across a broad portfolio of technologies in cGMP Chemical & Biological custom manufacturing from early stage to late phase/commercial and gained significant experience and published and presented regularly on Highly Potent Active Pharmaceutical Ingredients (HPAPI, incl. ADC).

Mr. Janssen progressed a number of HPAPI programs from the clinic into the market and successfully managed capital investment strategies to enable this.

Mr. Janssen will present how a fully integrated service offering can be beneficial to drug developers in achieving their goals for delivering a cost-efficient final product.

Related Sessions:

Qepler - Highly Potent APIs Summit thumbnail

Details

Highly Potent APIs
Summit 2019

Assess and reduce manufacturing and handling challenges for highly potent active pharmaceutical ingredients.

20 Feb 2019
Berlin, DE
Pharma

Day 1: Wednesday, 20 February 2019

BLOCK: PROCESS ROBUSTNESS, SAFETY & EFFICIENCY.

CASE STUDY: Best practices: requirements for fully-integrated service-offerings in a HPAPI and cytotoxic environment.

Drug product development based on potent compounds can be quite challenging.
Complications with the interface between operations in drug substance and drug product handling can also result in increased program complexity and cost.
In this presentation, we will elaborate on best practices and infrastructure requirements that facilitate accelerated timelines to clinic and market:

Development, rapid scaling and commercial production of HPAPI drug substance
Integrated containment requirements for particle engineering and drug products
Impact of supporting integrated service-offerings on expansion strategies

View Details

Qepler - 2nd Annual Highly Potent APIs Summit thumbnail

Details

2nd Annual Highly Potent APIs
Summit 2020

Assess and reduce manufacturing and handling challenges for highly potent active pharmaceutical ingredients.

19 Feb 2020
Prague, CZ
Pharma

Day 1: Wednesday, 19 February 2020

CASE STUDY: APIs and Toxins/Linkers for Antibody Drug Conjugates: A Vision on Highly Potent Development, Scale-up and Manufacturing.

Drug product development based on potent compounds can be quite challenging.

Complications with the interface between operations in drug substance and drug product handling can also result in increased program complexity and cost. This also applies when the potent compound is used as toxin/linker for application in ADCs.

In this presentation, we will elaborate on best practices and requirements that facilitate accelerated timelines to clinic & market:

Development, rapid scaling and commercial production of HPAPI drug substance (incl. Case Study)
Integrated containment for particle engineering and drug products
Impact of supporting integrated service-offerings on expansion strategies